Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

Journal of Clinical Oncology

Volumn 27, Issue 28, 2009, Pages 4760-4766

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop M ^a   Manshouri, Taghi ^a   Thomas, Deborah ^a   Cortes, Jorge ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Bueso Ramos, Carlos ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; JANUS KINASE 2; LENALIDOMIDE; PREDNISONE; RETICULIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOID; JAK2 PROTEIN, HUMAN; PLATELET DERIVED GROWTH FACTOR; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ALLELE; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOID METAPLASIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLUCOCORTICOIDS; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NEUTROPENIA; PLATELET-DERIVED GROWTH FACTOR; PREDNISONE; PRIMARY MYELOFIBROSIS; THALIDOMIDE; THROMBOCYTOPENIA; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 70350439432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.6548     Document Type: Article

References (36)

1. Hoffman R, Rondelli D: Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program 2007:346-354, 2007
2. Arana-Yi C, Quintas-Cardama A, Giles F, et al: Advances in the therapy of chronic idiopathic myelo-fibrosis. Oncologist 11:929-943, 2006
3. Deeg HJ, Gooley TA, Flowers ME, et al: Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102:3912-3918, 2003
4. Rondelli D, Barosi G, Bacigalupo A, et al: Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediateor high-risk patients with myelofibrosis with myeloid metaplasia. Blood 105:4115-4119, 2005
5. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005
6. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148, 2005
7. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790, 2005
8. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397, 2005
9. Zhao R, Xing S, Li Z, et al: Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280:22788-22792, 2005
10. Shah N, Olszynski, P, Sokol, L, et al: A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis. Blood 112, 2008 (abstr 98)
11. Pardanani A, Gotlib J, Jamieson C, et al: A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis. Blood 112, 2008 (abstr 97)
12. Moliterno A, Roboz GJ, Carroll M, et al: An open-label study of CEP-701 in patients with JAK2 V617F-positive polycythemia vera and essential thrombocytosis. Blood 112, 2008 (abstr 99)
13. Verstovsek S, Kantarjian H, Pardanani A, et al: The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMF). Blood 112, 2008 (abstr 1762)
14. Schmitt A, Jouault H, Guichard J, et al: Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 96:1342-1347, 2000
15. Xu M, Bruno E, Chao J, et al: Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 105:4508-4515, 2005
16. Raje N, Anderson K: Thalidomide-a revival story. N Engl J Med 341:1606-1609, 1999
17. Abgrall JF, Guibaud I, Bastie JN, et al: Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: A prospective, randomized, doubleblind, multicenter study. Haematologica 91:1027-1032, 2006
18. Marchetti M, Barosi G, Balestri F, et al: Lowdose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial. J Clin Oncol 22:424-431, 2004
19. Mesa RA, Steensma DP, Pardanani A, et al: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534-2541, 2003
20. Tefferi A, Cortes J, Verstovsek S, et al: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108:1158-1164, 2006
21. Thiele J, Kvasnicka HM, Facchetti F, et al: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128-1132, 2005
22. Tefferi A, Barosi G, Mesa RA, et al: International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497-1503, 2006
23. McClure R, Mai M, Lasho T: Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20:168-171, 2006
24. Wang JC, Chang TH, Goldberg A, et al: Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 34:1617-1623, 2006
25. Schafer PH, Gandhi AK, Loveland MA, et al: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305:1222-1232, 2003
26. Bartlett JB, Dredge K, Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322, 2004
27. Tohnya TM, Hwang K, Lepper ER, et al: Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 811:135-141, 2004
28. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007
29. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007
30. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006
31. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005
32. Hirsh J: Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 131:275-277, 2007
33. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
34. Dong M, Blobe GC: Role of transforming growth factor-beta in hematologic malignancies. Blood 107:4589-4596, 2006
35. Mesa RA, Hanson CA, Rajkumar SV, et al: Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96:3374-3380, 2000
36. Arora B, Ho CL, Hoyer JD, et al: Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia. Haematologica 89: 1454-1458, 2004